Atezolizumab plus Bevacizumab as a downstaging therapy for liver transplantation in Hepatocellular carcinoma with portal vein thrombosis: The first report

Atezolizumab plus bevacizumab is the preferred first-line regimen for patients with advanced Hepatocellular carcinoma (HCC). Limited data have shown promising results with the use of immune checkpoint inhibitors like nivolumab to downstage these patients for liver transplantation. Here, we describe the first case of successful downstaging with atezolizumab plus bevacizumab in a patient with Multifocal HCC and main portal vein tumoral thrombosis (PVTT) followed by ABO-incompatible live donor liver transplantation (LDLT). This illustrated case highlights that atezolizumab plus bevacizumab therapy may be a potential bridging tool for curative liver transplantation.